Patient Derived Xenograft (PDX) models present a true representation of the human heterogeneity of gynecologic malignancies and provide the most accurate approach to predicting an agents efficacy prior to entering the clinic. The CrownBio ovarian cancer PDX collection consists several models including a treatment resistant model. Learn more about these models in the following publication: More
-Predictive Markers of Efficacy for an Angiopoietin-2 Targeting Therapeutic in Xenograft Models.pdf
Patient-derived xenografts (PDX) offer the most translational preclinical model for efficacy screening in cancer drug development. Derived directly from patient tumors and never adapted to grow in vitro, PDX models reflect the heterogeneity and diversity of the human patient population. PDX give you an accurate, predictive model of how your treatment will perform, well before entering into expensive clinical trials.
CrownBio’s HuPrime® PDX collection well characterized for pathology, growth characteristics, and are also genetically/genomically annotated for gene expression, gene copy number, mutations, and fusions.